JRCT ID: jRCT2080225347
Registered date:25/08/2020
Venetoclax in Combination with LDAC in Treatment-Naive Japanese AML Subjects in Expanded Access Study [M19-916]
Basic Information
| Recruitment status | completed |
|---|---|
| Health condition(s) or Problem(s) studied | |
| Date of first enrollment | 10/09/2020 |
| Target sample size | 38 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : venetoclax Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : |
Outcome(s)
| Primary Outcome | safety |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | >= 18age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | |
| Exclude criteria |
Related Information
| Primary Sponsor | AbbVie G.K. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) | NCT04509622,JapicCTI-205443 |
Contact
| Public contact | |
| Name | |
| Address | |
| Telephone | +81-120-587-874 |
| Affiliation | |
| Scientific contact | |
| Name | |
| Address | |
| Telephone | |
| Affiliation | |